Regeneron Initiates Quarterly Dividend and Expands Share Repurchase Program

Details

announced its financial results for the quarter and full year 2024, highlighting a 10% increase in fourth-quarter revenues to $3.79 billion and an 8% rise in full-year revenues to $14.20 billion. The company also initiated a quarterly cash dividend program, declaring a $0.88 per share dividend for its common and Class A stock, payable on March 20, 2025. Additionally, Regeneron authorized an additional $3.0 billion share repurchase program, increasing its total repurchase capacity to approximately $4.5 billion.

Items reported

Exhibits (1)

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.